Ciclopirox phosphoryloxymethyl ester - CicloMed

Drug Profile

Ciclopirox phosphoryloxymethyl ester - CicloMed

Alternative Names: Ciclopirox prodrug - CicloMed; CPX - CicloMed; CPX-POM

Latest Information Update: 29 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Kansas
  • Developer CicloMed; University of Kansas
  • Class Antifungals; Antineoplastics; Small molecules
  • Mechanism of Action Mitosis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Solid tumours
  • Preclinical Bladder cancer

Most Recent Events

  • 01 Jun 2018 Pharmacodynamics data from preclinical studies in Bladder cancer presented at the 54th Annual Meeting of the American Society of Clinical Oncology (ASCO-2018)
  • 15 Jan 2018 Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV) (NCT03348514)
  • 29 Nov 2017 CicloMed plans a phase I trial for Solid tumours (Late-stage disease, Second-line therapy or greater, Metastatic disease) in USA (IV) in January 2018 (NCT03348514)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top